Análise do processo de produção de semaglutida

Abstract

Chronic diseases such as diabetes and obesity are widely recognized by experts as defining illnesses of the 21st century, due to their high prevalence—currently affecting over 500 million people worldwide—and alarming growth projections for the coming decades. In this context, semaglutide stands out as a promising drug in combating these conditions, demonstrating significant clinical results, such as a 10% reduction in body weight in approximately 60% of patients. Marketed by Novo Nordisk under the brand names Rybelsus, Wegovy, and Ozempic, semaglutide gains additional relevance with its patent set to expire in 2026. Therefore, the main objective of this study is to analyze the industrial-scale production methods of semaglutide, based on a review of patents filed with the American, European, international, and Brazilian patent offices. Three patents were selected for detailed analysis, and their manufacturing processes were evaluated in terms of production costs and compared with the market value of the active pharmaceutical ingredient. The findings indicate that all selected patents demonstrated positive gross margins, highlighting the economic feasibility of producing this drug.